Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.
Identifieur interne : 001D60 ( PubMed/Corpus ); précédent : 001D59; suivant : 001D61Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.
Auteurs : Wilma A. Stolk ; Quirine A. Ten Bosch ; Sake J. De Vlas ; Peter U. Fischer ; Gary J. Weil ; Ann S. GoldmanSource :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Filaricides.
- drug therapy : Elephantiasis, Filarial.
- economics : Drug Therapy.
- methods : Drug Therapy.
- Computer Simulation, Costs and Cost Analysis, Female, Humans, Male, Treatment Outcome.
Abstract
The Global Program to Eliminate Lymphatic Filariasis (LF) has a target date of 2020. This program is progressing well in many countries. However, progress has been slow in some countries, and others have not yet started their mass drug administration (MDA) programs. Acceleration is needed. We studied how increasing MDA frequency from once to twice per year would affect program duration and costs by using computer simulation modeling and cost projections. We used the LYMFASIM simulation model to estimate how many annual or semiannual MDA rounds would be required to eliminate LF for Indian and West African scenarios with varied pre-control endemicity and coverage levels. Results were used to estimate total program costs assuming a target population of 100,000 eligibles, a 3% discount rate, and not counting the costs of donated drugs. A sensitivity analysis was done to investigate the robustness of these results with varied assumptions for key parameters. Model predictions suggested that semiannual MDA will require the same number of MDA rounds to achieve LF elimination as annual MDA in most scenarios. Thus semiannual MDA programs should achieve this goal in half of the time required for annual programs. Due to efficiency gains, total program costs for semiannual MDA programs are projected to be lower than those for annual MDA programs in most scenarios. A sensitivity analysis showed that this conclusion is robust. Semiannual MDA is likely to shorten the time and lower the cost required for LF elimination in countries where it can be implemented. This strategy may improve prospects for global elimination of LF by the target year 2020.
DOI: 10.1371/journal.pntd.0001984
PubMed: 23301115
Links to Exploration step
pubmed:23301115Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.</title><author><name sortKey="Stolk, Wilma A" sort="Stolk, Wilma A" uniqKey="Stolk W" first="Wilma A" last="Stolk">Wilma A. Stolk</name><affiliation><nlm:affiliation>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. w.stolk@erasmusmc.nl</nlm:affiliation></affiliation></author><author><name sortKey="Ten Bosch, Quirine A" sort="Ten Bosch, Quirine A" uniqKey="Ten Bosch Q" first="Quirine A" last="Ten Bosch">Quirine A. Ten Bosch</name></author><author><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J" last="De Vlas">Sake J. De Vlas</name></author><author><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name></author><author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S" last="Goldman">Ann S. Goldman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23301115</idno><idno type="pmid">23301115</idno><idno type="doi">10.1371/journal.pntd.0001984</idno><idno type="wicri:Area/PubMed/Corpus">001D60</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.</title><author><name sortKey="Stolk, Wilma A" sort="Stolk, Wilma A" uniqKey="Stolk W" first="Wilma A" last="Stolk">Wilma A. Stolk</name><affiliation><nlm:affiliation>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. w.stolk@erasmusmc.nl</nlm:affiliation></affiliation></author><author><name sortKey="Ten Bosch, Quirine A" sort="Ten Bosch, Quirine A" uniqKey="Ten Bosch Q" first="Quirine A" last="Ten Bosch">Quirine A. Ten Bosch</name></author><author><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J" last="De Vlas">Sake J. De Vlas</name></author><author><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name></author><author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S" last="Goldman">Ann S. Goldman</name></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Computer Simulation</term><term>Costs and Cost Analysis</term><term>Drug Therapy (economics)</term><term>Drug Therapy (methods)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Female</term><term>Filaricides (administration & dosage)</term><term>Humans</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Computer Simulation</term><term>Costs and Cost Analysis</term><term>Female</term><term>Humans</term><term>Male</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Global Program to Eliminate Lymphatic Filariasis (LF) has a target date of 2020. This program is progressing well in many countries. However, progress has been slow in some countries, and others have not yet started their mass drug administration (MDA) programs. Acceleration is needed. We studied how increasing MDA frequency from once to twice per year would affect program duration and costs by using computer simulation modeling and cost projections. We used the LYMFASIM simulation model to estimate how many annual or semiannual MDA rounds would be required to eliminate LF for Indian and West African scenarios with varied pre-control endemicity and coverage levels. Results were used to estimate total program costs assuming a target population of 100,000 eligibles, a 3% discount rate, and not counting the costs of donated drugs. A sensitivity analysis was done to investigate the robustness of these results with varied assumptions for key parameters. Model predictions suggested that semiannual MDA will require the same number of MDA rounds to achieve LF elimination as annual MDA in most scenarios. Thus semiannual MDA programs should achieve this goal in half of the time required for annual programs. Due to efficiency gains, total program costs for semiannual MDA programs are projected to be lower than those for annual MDA programs in most scenarios. A sensitivity analysis showed that this conclusion is robust. Semiannual MDA is likely to shorten the time and lower the cost required for LF elimination in countries where it can be implemented. This strategy may improve prospects for global elimination of LF by the target year 2020.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23301115</PMID><DateCreated><Year>2013</Year><Month>01</Month><Day>09</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.</ArticleTitle><Pagination><MedlinePgn>e1984</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0001984</ELocationID><Abstract><AbstractText>The Global Program to Eliminate Lymphatic Filariasis (LF) has a target date of 2020. This program is progressing well in many countries. However, progress has been slow in some countries, and others have not yet started their mass drug administration (MDA) programs. Acceleration is needed. We studied how increasing MDA frequency from once to twice per year would affect program duration and costs by using computer simulation modeling and cost projections. We used the LYMFASIM simulation model to estimate how many annual or semiannual MDA rounds would be required to eliminate LF for Indian and West African scenarios with varied pre-control endemicity and coverage levels. Results were used to estimate total program costs assuming a target population of 100,000 eligibles, a 3% discount rate, and not counting the costs of donated drugs. A sensitivity analysis was done to investigate the robustness of these results with varied assumptions for key parameters. Model predictions suggested that semiannual MDA will require the same number of MDA rounds to achieve LF elimination as annual MDA in most scenarios. Thus semiannual MDA programs should achieve this goal in half of the time required for annual programs. Due to efficiency gains, total program costs for semiannual MDA programs are projected to be lower than those for annual MDA programs in most scenarios. A sensitivity analysis showed that this conclusion is robust. Semiannual MDA is likely to shorten the time and lower the cost required for LF elimination in countries where it can be implemented. This strategy may improve prospects for global elimination of LF by the target year 2020.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stolk</LastName><ForeName>Wilma A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. w.stolk@erasmusmc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ten Bosch</LastName><ForeName>Quirine A</ForeName><Initials>QA</Initials></Author><Author ValidYN="Y"><LastName>de Vlas</LastName><ForeName>Sake J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter U</ForeName><Initials>PU</Initials></Author><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Ann S</ForeName><Initials>AS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 2008 Nov;135(13):1583-98</RefSource><PMID Version="1">19006602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 2000 Jul;16(7):298-302</RefSource><PMID Version="1">10858649</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2010;4(6):e728</RefSource><PMID Version="1">20628595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods Inf Med. 1998 Jan;37(1):97-108</RefSource><PMID Version="1">9550853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2006 Jun;100(4):345-61</RefSource><PMID Version="1">16762115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 1999 Sep;15(9):382-6</RefSource><PMID Version="1">10461168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2004 Nov;98(11):627-34</RefSource><PMID Version="1">15363642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2010 Feb;104(2):129-32</RefSource><PMID Version="1">19926104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2011 Aug 26;86(35):377-88</RefSource><PMID Version="1">21887884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2005 Jul;99(7):541-7</RefSource><PMID Version="1">15869771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 2010 Feb;88(2):154-8</RefSource><PMID Version="1">20428373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 2004 May;128(Pt 5):467-82</RefSource><PMID Version="1">15180315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2008 Dec;102(12):1201-6</RefSource><PMID Version="1">18554674</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 Jun 18-24;365(9477):2067-8</RefSource><PMID Version="1">15964428</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2004 Nov;20(11):499-502</RefSource><PMID Version="1">15471698</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2006 Mar 28;5:5</RefSource><PMID Version="1">16569234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2008 Dec;13(12):1430-2</RefSource><PMID Version="1">18983273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Indian J Med Res. 2000 Mar;111:81-9</RefSource><PMID Version="1">10937383</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Commun Dis. 1992 Jun;24(2):87-91</RefSource><PMID Version="1">1344177</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2005 Aug 02;4:7</RefSource><PMID Version="1">16076397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1996 Nov;55(5 Suppl):165-9</RefSource><PMID Version="1">8940971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 1991 Sep;22(3):402-11</RefSource><PMID Version="1">1818392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1997;75(6):491-503</RefSource><PMID Version="1">9509621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 2004 Nov;129(Pt 5):605-12</RefSource><PMID Version="1">15552405</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2004 Apr;98(4):205-17</RefSource><PMID Version="1">15049459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2007;1(1):e67</RefSource><PMID Version="1">17989784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2004 Feb;70(2):191-6</RefSource><PMID Version="1">14993632</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Exp Med Biol. 2010;673:157-71</RefSource><PMID Version="1">20632536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2005 Sep;99(9):664-8</RefSource><PMID Version="1">15992839</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3536806</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23301115</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0001984</ArticleId><ArticleId IdType="pii">PNTD-D-12-00392</ArticleId><ArticleId IdType="pmc">PMC3536806</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001D60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23301115
|texte= Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23301115" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |